Literature DB >> 33685433

CDCA8 as an independent predictor for a poor prognosis in liver cancer.

Yu Shuai1, Erxi Fan2, Qiuyue Zhong2, Qiying Chen2, Guangyong Feng2, Xiaoxia Gou2, Guihai Zhang3.   

Abstract

BACKGROUND: Human cell division cycle associated 8 (CDCA8) a key regulator of mitosis, has been described as a potential prognostic biomarker for a variety of cancers, such as breast, colon and lung cancers. We aimed to evaluate the potential role of CDCA8 expression in the prognosis of liver cancer by analysing data from The Cancer Genome Atlas (TCGA).
METHODS: The Wilcoxon rank-sum test was used to compare the difference in CDCA8 expression between liver cancer tissues and matched normal tissues. Then, we applied logistic regression and the Wilcoxon rank-sum test to identify the association between CDCA8 expression and clinicopathologic characteristics. Cox regression and the Kaplan-Meier method were used to examine the clinicopathologic features correlated with overall survival (OS) in patients from the TCGA. Gene set enrichment analysis (GSEA) was performed to explore possible mechanisms of CDCA8 according to the TCGA dataset.
RESULTS: CDCA8 expression was higher in liver cancer tissues than in matched normal tissues. Logistic regression and the Wilcoxon rank-sum test revealed that the increased level of CDCA8 expression in liver cancer tissues was notably related to T stage (OR = 1.64 for T1/2 vs. T3/4), clinical stage (OR = 1.66 for I/II vs. III/IV), histologic grade (OR = 6.71 for G1 vs. G4) and histological type (OR = 0.24 for cholangiocarcinoma [CHOL] vs. hepatocellular carcinoma [LIHC]) (all P-values < 0.05). Kaplan-Meier survival analysis indicated that high CDCA8 expression was related to a poor prognosis in liver cancer (P = 2.456 × 10-6). Univariate analysis showed that high CDCA8 expression was associated with poor OS in liver cancer patients, with a hazard ratio (HR) of 1.85 (95% confidence interval [CI]: 1.47-2.32; P = 1.16 × 10-7). Multivariate analysis showed that CDCA8 expression was independently correlated with OS (HR = 1.74; CI: 1.25-12.64; P = 1.27 × 10-5). GSEA revealed that the apoptosis, cell cycle, ErbB, MAPK, mTOR, Notch, p53 and TGF-β signaling pathways were differentially enriched in the CDCA8 high expression phenotype.
CONCLUSIONS: High CDCA8 expression is a potential molecular predictor of a poor prognosis in liver cancer.

Entities:  

Keywords:  CDCA8; Liver cancer; Prognosis; The Cancer Genome Atlas

Year:  2021        PMID: 33685433     DOI: 10.1186/s12935-021-01850-x

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  2 in total

1.  PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Authors:  Roberto Gedaly; Paul Angulo; Jonathan Hundley; Michael F Daily; Changguo Chen; Alvaro Koch; B Mark Evers
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

2.  Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.

Authors:  Chao Ci; Biao Tang; Dalun Lyu; Wenbei Liu; Di Qiang; Xiang Ji; Xiamin Qiu; Lei Chen; Wei Ding
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

  2 in total
  8 in total

1.  An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.

Authors:  Michail Sarafidis; George I Lambrou; Vassilis Zoumpourlis; Dimitrios Koutsouris
Journal:  Cancers (Basel)       Date:  2022-07-10       Impact factor: 6.575

2.  A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Authors:  Wenmin Hu; Yongmei Shi; Tongqin Han; Caiyun Liu; Xipeng Cao; Guangjun Shi; Wenjing Zhu
Journal:  Front Genet       Date:  2022-05-03       Impact factor: 4.772

3.  Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Xiao-Han Cui; Qiu-Ju Peng; Ren-Zhi Li; Xia-Jie Lyu; Chun-Fu Zhu; Xi-Hu Qin
Journal:  J Cell Mol Med       Date:  2021-11-05       Impact factor: 5.310

4.  An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.

Authors:  Zhiyun Xu; Shi Wang; Zhijian Ren; Xiang Gao; Lin Xu; Shuai Zhang; Binhui Ren
Journal:  World J Surg Oncol       Date:  2022-03-30       Impact factor: 2.754

5.  ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.

Authors:  Qiaoling Zhang; Yingmei Wang; Fengxia Xue
Journal:  Genet Res (Camb)       Date:  2022-09-17       Impact factor: 1.375

6.  A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.

Authors:  Zhihong Chen; Yiping Zou; Yuanpeng Zhang; Zhenrong Chen; Fan Wu; Ning Shi; Haosheng Jin
Journal:  J Clin Lab Anal       Date:  2021-09-15       Impact factor: 2.352

7.  High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma.

Authors:  Jianjun Xu; Zhe Su; Xiang Cheng; Shaobo Hu; Wenjie Wang; Tianhao Zou; Xing Zhou; Zifang Song; Yun Xia; Yang Gao; Qichang Zheng
Journal:  Cancer Cell Int       Date:  2022-03-11       Impact factor: 5.722

8.  Elevated Ras related GTP binding B (RRAGB) expression predicts poor overall survival and constructs a prognostic nomogram for colon adenocarcinoma.

Authors:  Jianjia Xiao; Qingqing Liu; Weijie Wu; Ying Yuan; Jie Zhou; Jieyu Shi; Shaorong Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.